C:\Program Files\Stnexp\Queries\10612014.str





chain nodes :
1 2 3 4 5 6 8 11
chain bonds :
1-2 1-6 2-3 2-11 3-4 4-5 5-8
exact/norm bonds :
2-3 2-11 3-4 4-5 5-8
exact bonds :
1-2 1-6

G1:O,S

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:Atom 8:CLASS 11:CLASS
Generic attributes :
6:
Saturation : Unsaturated

10/612014

```
=> s l1
SAMPLE SEARCH INITIATED 17:34:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     178 TO ITERATE

100.0% PROCESSED      178 ITERATIONS                                 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         2760 TO     4360
PROJECTED ANSWERS:               2 TO      124

L2             2 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 17:34:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    3888 TO ITERATE

100.0% PROCESSED     3888 ITERATIONS                               21 ANSWERS
SEARCH TIME: 00.00.01

L3            21 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             155.84     156.05

FILE 'CAPLUS' ENTERED AT 17:34:33 ON 16 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 16 Dec 2004  VOL 141 ISS 25
FILE LAST UPDATED: 15 Dec 2004  (20041215/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l3
L4             14 L3

=> d l4 1-14 bib abs hitstr
```

L4 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:739958 CAPLUS
DN 141:260542
TI Preparation of nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as selective cyclooxygenase-2 inhibitors
IN Berthelette, Carl; Li, Lianhai; Sturino, Claudio; Wang, Zhaoyin
PA Can.
SO U.S. Pat. Appl. Publ., 19 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004176331	A1	20040909	US 2004-790288	20040301
WO 2004103955	A1	20041202	WO 2004-CA314	20040301

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-452124P P 20030305
OS MARPAT 141:260542
GI



I



II

AB Title compds. I [X = (CH2)n; n = 3-6; R1 = SO2Me, SO2NH2, SO2NHCOCF3, etc.; R2, R3 = H, halo, alkoxy, etc.; R4 = CO-alkyl, CO(CH2)mNR5R6; m = 1-4; R5, R6 = H, halo-substituted alkyl] and their pharmaceutically

acceptable salts were prepared For example, O-alkylation of AgNO3 by bromide II (Z = Br), e.g., prepared from Rofecoxib in 6-steps, afforded nitrooxyhexyl II (Z = -ONO2). In human blood PGE2 inhibition production assays, nitrooxyhexyl II (Z = -ONO2) exhibited an IC50 value of 0.22 μM. Of note, the "unconverted prodrugs" of compds. I are inactive inhibitors of COX-1 and COX-2 activity. Compds. I are claimed useful for the treatment of cyclooxygenase-2 mediated diseases or conditions.

IT **754242-01-8P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nitric oxide releasing prodrugs of diarylfuranones as selective COX-2 inhibitors)

RN 754242-01-8 CAPLUS

CN Benzeneacetic acid, α-[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 7-(nitrooxy)heptyl ester, (αZ)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:267282 CAPLUS
DN 140:287165
TI Manufacturing process for NO-donating compounds such as NO-donating diclofenac
IN Andersson, Johan; Belli, Aldo; Cannata, Vincenzo; Hedberg, Martin; Palmgren, Andreas; Schuldei, Sigrid; Stroem, Marika; Villa, Marco
PA Astrazeneca UK Limited, UK; Astrazeneca AB
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004026808	A1	20040401	WO 2003-SE1465	20030918

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI SE 2002-2801 A 20020920
SE 2003-1476 A 20030520
OS CASREACT 140:287165; MARPAT 140:287165
AB NO-Donating compds. MLnAmCO2XONOp [M = residue of an NSAID, COX-1 inhibitor or COX-2 inhibitor; L = O, S, CO2, (un)substituted CONH, NH, CO, CH2, CH2CO, CH2CONH, CH2CO2; A = (un)substituted alkylene; X = carbon linker; m, n = 0-3; p= 1, 2] are prepared by treating MLnAmCO2H with HOXOH, treating MLnAmCO2XOH with RSO2Cl [R = alkyl, (un)substituted Ph, CH2Ph, halogen, CF3, C4F9], and treating MLnAmCO2XO3SR with nitrate. A substantially crystalline form of 2-[2-(nitrooxy)ethoxy]ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate is reported.
IT **676125-87-4P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(manufacturing process for NO-donating compds. such as NO-donating diclofenac)
RN 676125-87-4 CAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 2-[2-[2-(nitrooxy)ethoxy]ethoxy]ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:41217 CAPLUS
DN 140:111135
TI Preparation of nitrosated nonsteroidal antiinflammatory compounds
IN Earl, Richard A.; Ezawa, Maiko; Fang, Xinqin; Garvey, David S.; Gaston, Ricky D.; Khanapure, Subhash P.; Letts, Gordon L.; Lin, Chia-En; Ranatunge, Ramani R.; Richardson, Stewart K.; Schroeder, Joseph D.; Stevenson, Cheri A.; Wey, Shiow-Jyi
PA Nitromed, Inc., USA
SO PCT Int. Appl., 145 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004004648	A2	20040115	WO 2003-US21026	20030703
	WO 2004004648	A3	20041028		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004024057	A1	20040205	US 2003-612014	20030703
PRAI	US 2002-393111P	P	20020703		
	US 2002-397979P	P	20020724		
	US 2002-418353P	P	20021016		
	US 2003-449798P	P	20030226		
	US 2003-456182P	P	20030321		

OS MARPAT 140:111135
GI



II

AB Title compds. RnRmHC-CO-X [Rm = H, alkyl; Rn = 4-((thiophen-2-yl)carbonyl)phenyl, 3-(benzoyl)phenyl, etc.; X = Y-alkyl-aryl, etc.; Y = O, S; I] are prepared For instance, naproxen is coupled to 2,2'-thiodiethanol (CH2Cl2, DMAP, EDCI) and treated with Ac2O/HNO3 at 0° to give II. I are nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) used alone or are combined with one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase. The invention provides methods for treating inflammation, pain, fever, gastrointestinal disorders, etc.
IT **646509-75-3P**, 2-[[N-[2-(Nitrooxy)ethyl]carbamoyl]oxy]ethyl

(2S)-2-(6-methoxy-2-naphthyl)propanoate **646509-99-1P**,
[N-Methyl-N-[[[[2-(nitrooxy)ethyl]oxy]carbonyl]methyl]carbamoyl]methyl
(2S)-2-(6-methoxy-2-naphthyl)propanoate **646510-05-6P**,
[N-Methyl-N-[[[[3-(nitrooxy)propyl]oxy]carbonyl]methyl]carbamoyl]methyl
(2S)-2-(6-methoxy-2-naphthyl)propanoate **646510-09-0P**,
[N-Methyl-N-[[N-[2-(nitrooxy)ethyl]carbamoyl]methyl]carbamoyl]methyl
(2S)-2-(6-methoxy-2-naphthyl)propanoate **646510-17-0P**,
[[[2-[[2-(Nitrooxy)ethyl]sulfonyl]ethyl]oxy]carbonyl]methyl
(2S)-2-(6-methoxy-2-naphthyl)propanoate **646510-88-5P**,
2-[[(2S)-2-(6-Methoxy-2-naphthyl)propanoyl]oxy]ethyl 3-(nitrooxy)propyl
ethane-1,2-dioate **646511-50-4P**, [[[2-[[2-
(Nitrooxy)ethyl]sulfonyl]ethyl]oxy]carbonyl]methyl 2-(6-methoxy-2-
naphthyl)propanoate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of naproxen-derived nitrosated antiinflammatory compds.)

RN 646509-75-3 CAPLUS
CN 2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, 2-[[[[2-
(nitrooxy)ethyl]amino]carbonyl]oxy]ethyl ester, (αS)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



RN 646509-99-1 CAPLUS
CN 2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, 2-[methyl[2-[2-
(nitrooxy)ethoxy]-2-oxoethyl]amino]-2-oxoethyl ester, (αS)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 646510-05-6 CAPLUS
CN 2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, 2-[methyl[2-[3-
(nitrooxy)propoxy]-2-oxoethyl]amino]-2-oxoethyl ester, (αS)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 646510-09-0 CAPLUS
CN 2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, 2-[methyl[2-[[2-(nitrooxy)ethyl]amino]-2-oxoethyl]amino]-2-oxoethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646510-17-0 CAPLUS
CN 2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, 2-[2-[[2-(nitrooxy)ethyl]sulfonyl]ethoxy]-2-oxoethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646510-88-5 CAPLUS
CN Ethanedioic acid, 2-[(2S)-2-(6-methoxy-2-naphthalenyl)-1-oxopropoxy]ethyl 3-(nitrooxy)propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646511-50-4 CAPLUS
CN 2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, 2-[2-[[2-(nitrooxy)ethyl]sulfonyl]ethoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:2684 CAPLUS
DN 140:73178
TI Nitroxy derivatives of non-steroidal anti-inflammatory compounds as selective inhibitors of cyclooxygenase-2 for the treatment of inflammation
IN Del Soldato, Piero; Santus, Giancarlo
PA Nicox S.A., Fr.
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004000300	A1	20031231	WO 2003-EP6651	20030624

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI IT 2002-MI1399 A 20020625
OS MARPAT 140:73178
AB The present invention relates to compds. able to inhibit selectively the enzyme cyclooxygenase-2 (COX-2) without inhibiting substantially the enzyme COX-1. Specifically, the present invention concerns nitroxy derivs. of non-steroidal anti-inflammatory compds., which are able to inhibit selectively the enzyme COX-2. The compds. of the invention are useful in the treatment and/or prophylaxis of inflammatory processes.
IT **302543-75-5 302543-76-6 302543-77-7**
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitroxy derivs. of non-steroidal anti-inflammatory compds. as selective inhibitors of cyclooxygenase-2 for treatment of inflammation)
RN 302543-75-5 CAPLUS
CN D-Cysteine, N-acetyl-, 4-(nitrooxy)butyl ester, (αS)-6-methoxy-α-methyl-2-naphthaleneacetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 302543-76-6 CAPLUS
CN D-Cysteine, N-acetyl-, 4-(nitrooxy)butyl ester, α-methyl-4-(2-methylpropyl)benzeneacetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 302543-77-7 CAPLUS
CN D-Cysteine, N-acetyl-, 4-(nitrooxy)butyl ester, 2-fluoro-α-methyl[1,1'-biphenyl]-4-acetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:2666 CAPLUS
DN 140:65191
TI Oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability
IN Del Soldato, Piero; Santus, Giancarlo; Macelloni, Cristina
PA Nicox S.A., Fr.
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004000273	A1	20031231	WO 2003-EP6496	20030620

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI IT 2002-MI1392 A 20020625
GI



I

AB The present invention relates to new pharmaceutical compns. for the administration of liquid drugs in solid oral forms, said compns. comprising one or more active ingredients, one or more surface-active agents and optionally a co-surfactant and/or an absorption enhancer absorbed on a solid inert carrier. An emulsion was prepared containing I 100, Cremophor EL 50, Phospholipon 80H 50, Aerosil 200 100, and Explotab 100 g.

IT **639067-65-5 639067-67-7 639067-69-9**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

RN 639067-65-5 CAPLUS
CN 2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, 10-(nitrooxy)decyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 639067-67-7 CAPLUS
CN L-Cysteine, N-acetyl-, 4-(nitrooxy)butyl ester, α-methyl-4-(2-methylpropyl)benzeneacetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 639067-69-9 CAPLUS
CN L-Cysteine, N-acetyl-, 4-(nitrooxy)butyl ester, 2-fluoro-α-methyl[1,1'-biphenyl]-4-acetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:818296 CAPLUS
DN 139:302040
TI Nitrooxy derivatives of antiinflammatory/analgesic compounds for the treatment of arthritis
IN Del Soldato, Piero
PA Nicox S.A., Fr.
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003084550	A1	20031016	WO 2003-EP3183	20030327
W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, SG, TN, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI IT 2002-MI773	A	20020411		

OS MARPAT 139:302040
AB Antiinflammatory and/or antiinflammatory/analgesic compds. having the formula A(B)b0(C)c0-N(O)s [A contains radical of nonsteroidal antiinflammatory or nonsteroidal antiinflammatory/analgesic drug; B, C = bivalent linking group; s = 1, 2; b0, c0 = 0, 1 (with proviso)], and salts thereof, are disclosed for use in the treatment of arthritis.
IT **302543-75-5 497818-53-8 612478-28-1**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitrooxy derivs. of antiinflammatory/analgesic compds. for treatment of arthritis)
RN 302543-75-5 CAPLUS
CN D-Cysteine, N-acetyl-, 4-(nitrooxy)butyl ester, (αS)-6-methoxy-α-methyl-2-naphthaleneacetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497818-53-8 CAPLUS
CN L-Cysteine, N-acetyl-, 4-(nitrooxy)butyl ester, (αS)-2-fluoro-α-methyl[1,1'-biphenyl]-4-acetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612478-28-1 CAPLUS
CN L-Cysteine, N-acetyl-, 4-(nitrooxy)butyl ester, (αS)-α-methyl-4-(2-methylpropyl)benzeneacetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:499717 CAPLUS
DN 140:314514
TI Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: Evidence of a tissue type-independent effect. [Erratum to document cited in CA138:378736]
AU Kashfi, Khosrow; Rayyan, Yaser; Qiao, Leon L.; Williams, Jennie L.; Chen, Jie; Del Soldato, Piero; Traganos, Frank; Rigas, Basil
CS American Health Foundation, Valhalla, NY, USA
SO Journal of Pharmacology and Experimental Therapeutics (2003), 306(1), 421
CODEN: JPETAB; ISSN: 0022-3565
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
AB The name of the second author, Yaser Rayyan, was misspelled.
IT **302543-76-6**, NCX 2111
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibition of growth of various cultured human cancer cells and evidence of tissue type-independent effect (Erratum))
RN 302543-76-6 CAPLUS
CN D-Cysteine, N-acetyl-, 4-(nitrooxy)butyl ester, α-methyl-4-(2-methylpropyl)benzeneacetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:133017 CAPLUS
DN 138:163547
TI Nitrooxy compounds for treatment of vasculopaties
IN Del Soldato, Piero
PA Nicox S.A., Fr.
SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003013499	A2	20030220	WO 2002-EP8374	20020726
WO 2003013499	A3	20031231		

W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SG, SI, SK, TN, TR, TT, UA, US, UZ, VN, YU, ZA
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI IT 2001-MI1744 A 20010809
OS MARPAT 138:163547
AB The invention discloses the use for vasculopathy treatment of nitrooxy compds. (Markush included), or salts thereof. Compds. of the invention include e.g. 2-fluoro-α-methyl-4-diphenylacetic acid (4-nitrooxy)butyl ester (NO-flurbiprofen).
IT **302543-75-5 497818-53-8**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitrooxy compds. for treatment of vasculopaties)
RN 302543-75-5 CAPLUS
CN D-Cysteine, N-acetyl-, 4-(nitrooxy)butyl ester, (αS)-6-methoxy-α-methyl-2-naphthaleneacetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497818-53-8 CAPLUS
CN L-Cysteine, N-acetyl-, 4-(nitrooxy)butyl ester, (αS)-2-fluoro-α-methyl[1,1'-biphenyl]-4-acetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Me
NHAc
F
S
S
R
O
O
O
O
(CH2)4
NO2
Ph

L4 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:932594 CAPLUS
DN 138:378736
TI Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect
AU Kashfi, Khosrow; Ryann, Yassir; Qiao, Leon L.; Williams, Jennie L.; Chen, Jie; Del Soldato, Piero; Traganos, Frank; Rigas, Basil
CS American Health Foundation, Valhalla, NY, USA
SO Journal of Pharmacology and Experimental Therapeutics (2002), 303(3), 1273-1282
CODEN: JPETAB; ISSN: 0022-3565
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
AB The novel nitric oxide (NO)-donating nonsteroidal anti-inflammatory drugs (NO-NSAIDs), which are safer than their NSAID counterparts, inhibit the growth of colon cancer cells with far greater potency than traditional NSAIDs. We examined whether NO-NSAIDs inhibit the growth of cancer cells arising from other human tissues. Human pancreatic, colon, prostate, lung, and tongue cancer cell lines were treated with NO-aspirin, -sulindac, -ibuprofen, and -indomethacin or their traditional counterparts. We determined IC50 values, cell proliferation, apoptosis, cell cycle, cyclooxygenase (COX) protein levels, and morphol. changes (light and electron microscopy). All NO-NSAIDs inhibited the growth of all cancer cell lines studied. The potency of NO-NSAIDs was 11- to 6000-fold greater than that of their counterparts (except for the effect of sulindac on lung cancer cells). NO-aspirin was consistently the most potent NO-NSAID in all cell lines tested (except for the lung cancer cell line), sometimes in excess of 100-fold over the other three NO-NSAIDs. NO-NSAIDs inhibited cell proliferation, induced apoptosis, and altered cell cycle phase distribution (G2/M to G0/G1 block). All altered cellular morphol., whereas NO-aspirin induced nuclear disintegration ("atypical" cells) established by electron microscopy. NO-aspirin showed similar effects on two pancreatic cancer cell lines, BxPC-3 (expresses COX) and MIA PaCa-2 (no COX expression), suggesting a COX-independent effect. NO-NSAIDs showed a tissue-type-independent effect. Their pleiotropic effects involve cell renewal, cell death, and cell cycle phase transitions. These results raise the possibility that NO-NSAIDs possess chemopreventive and/or chemotherapeutic activity against a wide variety of human cancers.
IT **302543-76-6**, NCX 2111
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibition of growth of various cultured human cancer cells and evidence of tissue type-independent effect)
RN 302543-76-6 CAPLUS
CN D-Cysteine, N-acetyl-, 4-(nitrooxy)butyl ester, α-methyl-4-(2-methylpropyl)benzeneacetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:888544 CAPLUS
DN 137:369833
TI Preparation of nitrooxy cysteine derivatives for the Alzheimer's disease
IN Del Soldato, Piero
PA Nicox S.A., Fr.
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002092072	A2	20021121	WO 2002-EP5165	20020510
	WO 2002092072	A3	20030501		

W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI IT 2001-MI985 A 20010515
OS MARPAT 137:369833
GI



II

AB Title compds. A-Bn-Cm-NO2 [n, m = 0-1 with the proviso that m, n cannot be contemporaneously equal to 0; A = R-T1; R = (hetero)cycle; T1 = (CO)0-1, X0-1; X = O, S, amino; B = T2-X2-T3; T2-3 = CO, X, etc.; X2 = bivalent linking group; C = bivalent linking radical; I] were prepared For instance, 6-methoxy-α-methyl-2-naphthalenacetic acid was coupled to (S)-N-acetylcysteine (DMF/CHCl3, CDI, 12 h), the product converted to the 4-bromobutyl ester (THF, Ph3P, CBr4, 24 h) and that intermediate treated with AgNO3 (CH3CN, reflux, 7 h) to afford II. Nitrooxy derivs. of the invention are effective in inhibiting LPS-induced neurodegeneration and are useful in the treatment of Alzheimer's disease.

IT **302543-75-5P 302543-76-6P 302543-77-7P**
475561-35-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrooxy cysteine derivs. and related analogs for Alzheimer's disease)

RN 302543-75-5 CAPLUS
CN D-Cysteine, N-acetyl-, 4-(nitrooxy)butyl ester, (αS)-6-methoxy-α-methyl-2-naphthaleneacetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 302543-76-6 CAPLUS
CN D-Cysteine, N-acetyl-, 4-(nitrooxy)butyl ester, α-methyl-4-(2-methylpropyl)benzeneacetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 302543-77-7 CAPLUS
CN D-Cysteine, N-acetyl-, 4-(nitrooxy)butyl ester, 2-fluoro-α-methyl[1,1'-biphenyl]-4-acetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 475561-35-4 CAPLUS
CN D-Cysteine, N-acetyl-, 4-(nitrooxy)butyl ester, 2-[(2,6-dichlorophenyl)amino]benzeneacetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:293592 CAPLUS
DN 136:325420
TI Drugs for diabetes, especially type 2, comprising an antiinflammatory or analgesic drug, selected bivalent linkers, and a nitrate ester
IN Del Soldato, Piero
PA Nicox S.A., Fr.
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002030867	A2	20020418	WO 2001-EP11665	20011009
	WO 2002030867	A3	20020725		
	W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	IT 1319201	B1	20030926	IT 2000-MI2201	20001012
	CA 2425655	AA	20020418	CA 2001-2425655	20011009
	AU 2002014006	A5	20020422	AU 2002-14006	20011009
	EP 1324974	A2	20030709	EP 2001-982414	20011009
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004511456	T2	20040415	JP 2002-534256	20011009
	US 2004023890	A1	20040205	US 2003-398511	20030411
PRAI	IT 2000-MI2201	A	20001012		
	WO 2001-EP11665	W	20011009		

OS MARPAT 136:325420
GI



II

AB Useful for the treatment of diabetes, particularly type 2, are compds. or salts thereof, having the following general formula A-(B)n-(C)m-NO2 [I; wherein A = radical of a drug having an antiinflammatory or analgesic activity; B = bivalent linking group wherein the precursor must meet certain tests described in the application; C = another defined bivalent linking group; n and m = 0 or 1, provided that (n + m) = 1 or 2]. I can be used in conjunction with other antidiabetic drugs, particularly insulin. I increase the direct antidiabetic effect of insulin, and reduce complications of diabetes, particularly vascular diseases, retinopathies,

neuropathies, etc.. The values of n and m, i.e., the presence or absence of bivalent linkers B and C, alone or in combination, are based on performance of the precursors of the linkers in certain tests (no data). These tests are designated as follows: (test 4A): inhibition by > 15% of hemolysis of rat erythrocytes induced by cumene hydroperoxide; (test 5): inhibition of radical production by ≥ 50% in the oxidative degradation of . desoxyribose in aqueous Fe2+(NH4)2(SO4)2/thiobarbituric acid solution; and (test 4): inhibition by ≥ 50% of DPPH-induced radical production in MeOH solution For instance, acetylsalicylic acid chloride was esterified with 3-(hydroxymethyl)phenol (80%), followed by nitation of the resultant Ph ester with HNO3/H2SO4 (82%), to give invention compound II, which is thus the 3-(nitrooxymethyl)phenyl ester of aspirin. When tested on isolated aorta from insulin-resistant rats, compound II at a concentration of 10-4 M gave 70% vasorelaxation, relative to non-insulin-resistant controls. This effect was unchanged by the presence or absence of the irreversible NO synthetase inhibitor LNNA. In contrast, both Na nitroprussiate and the indomethacin analog of II, known NO donors, were inactive, and the antidiabetic drug metformin was inactivated by LNNA.

IT **302543-76-6P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of antidiabetic agents comprising antiinflammatory or analgesic drugs, selected bivalent linkers, and nitrate esters)

RN 302543-76-6 CAPLUS

CN D-Cysteine, N-acetyl-, 4-(nitrooxy)butyl ester, α-methyl-4-(2-methylpropyl)benzeneacetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:293591 CAPLUS
DN 136:309852
TI Preparation of nitrooxyalkylarenes as antiinflammatories and anticancer drugs.
IN Del Soldato, Piero; Benedini, Francesca; Antognazza, Patrizia
PA Nicox S.A., Fr.
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002030866	A1	20020418	WO 2001-EP11664	20011009
	W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	IT 1319202	B1	20030926	IT 2000-MI2202	20001012
	CA 2425649	AA	20020418	CA 2001-2425649	20011009
	AU 2002015932	A5	20020422	AU 2002-15932	20011009
	EP 1339665	A1	20030903	EP 2001-986670	20011009
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004511455	T2	20040415	JP 2002-534255	20011009
	US 2004023933	A1	20040205	US 2003-398289	20030410
PRAI	IT 2000-MI2202	A	20001012		
	WO 2001-EP11664	W	20011009		

OS MARPAT 136:309852
AB AX1LWpNO2 [p = 0, 1; A = RT1; R = specified precursor drug radicals; T1 = (CO)t, Xtt; X = O, S, imino, etc.; X1 = TbYTbb; Tb = CO, X; Tbb = (CO)xx, Xxxx; t, tt, xx, xxx = 0, 1; Y, Yt = specified bivalent linker; W = YtO; with provisos], were prepared Thus, acetylsalicylic acid in DMF was treated with NaOEt; after 30 min. the solution was added to a solution of bis(chloromethyl)pyridine (preparation given) in DMF; the mixture was kept 7 days to give 2-acetyloxybenzoic acid 6-chloromethyl-2-methylpyridinyl ester. The latter was heated with AgNO3 in MeCN at 80° for 30 min. to give 2-acetyloxybenzoic acid 6-nitrooxymethyl-2-methylpyridinyl ester. The latter at 10 μM gave 100% inhibition of HT29 cancer cells.
IT **302543-75-5**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of nitrooxyalkylarenes as antiinflammatories and anticancer drugs)
RN 302543-75-5 CAPLUS
CN D-Cysteine, N-acetyl-, 4-(nitrooxy)butyl ester, (αS)-6-methoxy-α-methyl-2-naphthaleneacetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:742053 CAPLUS
DN 133:310142
TI Synthesis, activity and formulations of pharmaceutical compounds for treatment of oxidative stress and/or endothelial dysfunction
IN Del Soldato, Piero
PA Nicox S.A., Fr.
SO PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061537	A2	20001019	WO 2000-EP3234	20000411
	WO 2000061537	A3	20010927		
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	IT 1311924	B1	20020320	IT 1999-MI753	19990413
	CA 2370412	AA	20001019	CA 2000-2370412	20000411
	BR 2000009702	A	20020108	BR 2000-9702	20000411
	EP 1169294	A2	20020109	EP 2000-925203	20000411
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002541233	T2	20021203	JP 2000-610814	20000411
	NZ 514267	A	20040625	NZ 2000-514267	20000411
	RU 2237657	C2	20041010	RU 2001-127576	20000411
	ZA 2001008127	A	20030103	ZA 2001-8127	20011003
	NO 2001004927	A	20011213	NO 2001-4927	20011010
PRAI	IT 1999-MI753	A	19990413		
	WO 2000-EP3234	W	20000411		

OS MARPAT 133:310142
AB Compds. A-B-C-N(O)s and A-C1[N(O)s]-B1 or their salts [s is an integer 1 or 2, preferably s = 2; A is the radical of a drug and is such as to meet the pharmacol. tests reported in the description; C and C1 are two bivalent radicals; the precursors of the radicals B and B1 are such as to meet the pharmacol. test reported in the description] were prepared for use as pharmaceuticals. Thus, (S,S)-N-acetyl-S-(6-methoxy-α-methyl-2-naphthalenylacetyl)cysteine 4-nitroxybutyl ester was prepared (NCX 2101) from naproxene and N-acetylcysteine in the first of 28 synthetic examples given. Pharmacol. test examples and tabular data are also given.
IT **302543-75-5P**, NCX 2101 **302543-76-6P**, NCX 2111
302543-77-7P, NCX 2131 **302543-81-3P**, NCX 2136
302543-98-2P, NCX 2061
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)
RN 302543-75-5 CAPLUS
CN D-Cysteine, N-acetyl-, 4-(nitrooxy)butyl ester, (αS)-6-methoxy-α-methyl-2-naphthaleneacetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 302543-76-6 CAPLUS
CN D-Cysteine, N-acetyl-, 4-(nitrooxy)butyl ester, α-methyl-4-(2-methylpropyl)benzeneacetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 302543-77-7 CAPLUS
CN D-Cysteine, N-acetyl-, 4-(nitrooxy)butyl ester, 2-fluoro-α-methyl[1,1'-biphenyl]-4-acetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 302543-81-3 CAPLUS
CN D-Cysteine, N-acetyl-, 4-(nitrooxy)butyl ester, (αS)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 302543-98-2 CAPLUS
CN D-Valine, 3-[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]thio]-, 4-(nitrooxy)butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:681459 CAPLUS
DN 125:328304
TI Preparation of nitric esters of 2-(2,6-dihalophenylamino)phenylacetoxyacetic acid derivatives
IN Serra, Masia Xavier; Pi Sallent, Joan
PA Prodes, S.A., Spain
SO Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 738706	A1	19961023	EP 1996-106009	19960417
	EP 738706	B1	19981007		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	ES 2092962	A1	19961201	ES 1995-756	19950419
	ES 2092962	B1	19970716		
	AU 9650428	A1	19961031	AU 1996-50428	19960401
	AU 683790	B2	19971120		
	ZA 9602981	A	19961022	ZA 1996-2981	19960415
	CA 2174287	AA	19961020	CA 1996-2174287	19960416
	CN 1138027	A	19961218	CN 1996-105067	19960417
	AT 171936	E	19981015	AT 1996-106009	19960417
	NO 9601537	A	19961021	NO 1996-1537	19960418
	JP 09020738	A2	19970121	JP 1996-98815	19960419
	US 5844696	A	19981201	US 1996-634763	19960419
	BR 9603235	A	19980428	BR 1996-3235	19960731
PRAI	ES 1995-756	A	19950419		

OS CASREACT 125:328304; MARPAT 125:328304
GI



I

AB The title compds. [I; A = F, Cl, Br; X = O, NH, NR (R = C1-8 alkyl); R1, R2 = C1-8 alkyl, n = 1-10], potentially useful as antiinflammatory agents (no data), were prepared by condensation of 2-(2,6-dihalophenylamino)phenylacetoxyacetic acid with a compound Y-(C)nR1R2ONO2 [Y = OH, NH2, NHR] in the presence of condensing agent such as N,N'-carbonyl diimidazole in an aprotic organic solvent.

IT **183195-07-5P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of nitric esters of 2-(2,6-dihalophenylamino)phenylacetoxyaceti
c acid derivs.)

RN 183195-07-5 CAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 2-[4-(nitrooxy)butoxy]-
2-oxoethyl ester (9CI) (CA INDEX NAME)



10/612014

```
=> file caold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    67.96     224.01

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -9.80      -9.80

FILE 'CAOLD' ENTERED AT 17:36:18 ON 16 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.

  This file supports REG1stRY for direct browsing and searching of
  all substance data from the REGISTRY file.  Enter HELP FIRST for
  more information.

=> s l3
L5            0 L3

=> log h
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.42     224.43

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -9.80

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 17:36:27 ON 16 DEC 2004
```